{
    "title": "115_s1276",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Cannabidiol Research Expansion \nAct''.\n\nSEC. 2. DEFINITIONS.\n\n    In this Act--\n            (1) the term ``authorized medical research'' means medical \n        research that is--\n                    (A) a preclinical study or clinical investigation \n                conducted in accordance with section 505(i) of the \n                Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) \n                or otherwise permitted by the Department of Health and \n                Human Services to determine the potential medical \n                benefits of marihuana or cannabidiol as a drug; and\n                    (B) conducted by a covered institution of higher \n                education, practitioner, or manufacturer that is \n                appropriately registered under the Controlled \n                Substances Act (21 U.S.C. 801 et seq.);\n            (2) the term ``cannabidiol'' means the nonpsychoactive \n        substance, cannabidiol, as derived from marihuana or the \n        synthetic formulation;\n            (3) the terms ``controlled substance'', ``dispense'', \n        ``distribute'', ``manufacture'', ``marihuana'', and \n        ``practitioner'' have the meanings given such terms in section \n        102 of the Controlled Substances Act (21 U.S.C. 802);\n            (4) the term ``covered institution of higher education'' \n        means an institution of higher education (as defined in section \n        101 of the Higher Education Act of 1965 (20 U.S.C. 1001)) \n        that--\n                    (A)(i) has highest or higher research activity, as \n                defined by the Carnegie Classification of Institutions \n                of Higher Education; or\n                    (ii) is an accredited medical school or an \n                accredited school of osteopathic medicine; and\n                    (B) is appropriately registered under the \n                Controlled Substances Act (21 U.S.C. 801 et seq.);\n            (5) the term ``drug'' has the meaning given the term in \n        section 201(g)(1) of the Federal Food Drug and Cosmetics Act \n        (21 U.S.C. 321(g)(1));\n            (6) the term ``registered manufacturer'' means an \n        individual or entity who is appropriately registered to \n        manufacture controlled substances under the Controlled \n        Substances Act (21 U.S.C. 801 et seq.), including an individual \n        or entity appropriately registered to manufacture controlled \n        substances as part of research; and\n            (7) the term ``State'' means any State of the United \n        States, the District of Columbia, and any territory of the \n        United States.\n\nSEC. 3. PROCEEDINGS FOR CONTROL, TRANSFER, OR REMOVAL OF CANNABIDIOL.\n\n    (a) Scientific and Medical Evaluations.--Not later than 1 year \nafter the date of enactment of this Act, the Attorney General and the \nSecretary of Health and Human Services shall each complete the \nscientific and medical evaluation described in section 201(b) of the \nControlled Substances Act (21 U.S.C. 811(b)) as to cannabidiol, which \nshall take into consideration the factors described in paragraphs (1) \nthrough (8) of subsection (c) of section 201 of that Act (21 U.S.C. \n811(c)).\n    (b) Proceedings To Control, Transfer, or Remove Cannabidiol.--After \ntaking into consideration the evaluation described in subsection (a), \nif the Attorney General determines that the evaluations, \nrecommendations, and all other relevant data warrant control, transfer, \nor removal of cannabidiol, the Attorney General shall initiate \nproceedings for control, transfer, or removal under section 201(a) of \nthe Controlled Substances Act (21 U.S.C. 811(a)).\n\nSEC. 4. RESEARCH PROTOCOLS.\n\n    The Attorney General shall amend section 1301.18 of title 21, Code \nof Federal Regulations (as in effect on the date of enactment of this \nAct), by striking subsections (c) and (d) and inserting the following:\n    ``(c) In the event that the registrant desires to increase the \nquantity of a controlled substance used for an approved research \nproject, he/she shall submit a request to the Registration Unit, Drug \nEnforcement Administration, by registered mail, return receipt \nrequested. See the Table of DEA Mailing Addresses in Sec.  1321.01 of \nthis chapter for the current mailing address. The request shall contain \nthe following information: DEA registration number; name of the \ncontrolled substance or substances and the quantity of each authorized \nin the approved protocol; and the additional quantity of each desired. \nUpon return of the receipt, the registrant shall be authorized to \npurchase and use the additional quantity of the controlled substance or \nsubstances specified in the request.\n    ``(d) In the event the registrant desires to conduct research \nbeyond the variations provided in the registrant's approved protocol \n(excluding any increase in the quantity of the controlled substance \nrequested for his/her research project as outlined in paragraph (c) of \nthis section), he/she shall submit three copies by registered mail, \nwith a return receipt requested, of a supplemental protocol in \naccordance with paragraph (a) of this section describing the new \nresearch and omitting information in the supplemental protocol which \nhas been stated in the original protocol. Unless explicitly denied, \nsupplemental protocols shall be considered approved 30 days after the \ndate on which the return receipt is returned.''.\n\nSEC. 5. MEDICAL RESEARCH ON CANNABIDIOL.\n\n    (a) In General.--Notwithstanding any provision of the Controlled \nSubstances Act (21 U.S.C. 801 et seq.), the Safe and Drug-Free Schools \nand Communities Act (20 U.S.C. 7101 et seq.), chapter 81 of title 41, \nUnited States Code, or any other Federal law, an appropriately \nregistered covered institution of higher education, a practitioner, or \na manufacturer may manufacture, distribute, dispense, or possess \nmarihuana or cannabidiol if the marihuana or cannabidiol is \nmanufactured, distributed, dispensed, or possessed, respectively, for \npurposes of authorized medical research.\n    (b) Registration for Research Involving Cannabidiol.--\n            (1) Initial period.--During the period beginning on the \n        date of enactment of this Act and ending on the date on which \n        the Attorney General makes a determination regarding control of \n        cannabidiol, an individual or entity engaged in authorized \n        medical research may distribute, dispense, or possess \n        cannabidiol for purposes of the authorized medical research if \n        the individual or entity is registered under the Controlled \n        Substances Act (21 U.S.C. 801 et seq.) to engage in such \n        activity with a controlled substance in schedule II in section \n        202(c) of the Controlled Substances Act (21 U.S.C. 812(c)).\n            (2) Completion of ongoing research.--If, as a result of the \n        determination and proceedings described in section 3, \n        cannabidiol is a controlled substance in schedule I in section \n        202(c) of the Controlled Substances Act (21 U.S.C. 812(c)), an \n        individual or entity engaged in authorized medical research may \n        continue to distribute, dispense, or possess cannabidiol for \n        purposes of completing the authorized medical research if the \n        individual or entity--\n                    (A) was engaged in the authorized medical research \n                in accordance with paragraph (1) on or before the date \n                on which the proceedings are completed; and\n                    (B) is registered under the Controlled Substances \n                Act (21 U.S.C. 801 et seq.) to engage in such activity \n                with a controlled substance in schedule II in section \n                202(c) of the Controlled Substances Act (21 U.S.C. \n                812(c)).\n    (c) Registration for the Commercial Production and Distribution of \nFood and Drug Administration Approved Drugs.--The Attorney General \nshall register an applicant to manufacture or distribute cannabidiol or \nmarihuana for the purpose of commercial production of a drug containing \nor derived from marihuana that is approved by the Secretary of Health \nand Human Services under section 505 of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 355), in accordance with the applicable \nrequirements under subsection (a) or (b) of section 303 of the \nControlled Substances Act (21 U.S.C. 823).\n    (d) Timely Processing of Registration Applications.--\n            (1) In general.--Not later than 60 days after the Attorney \n        General receives an application for registration under the \n        Controlled Substances Act (21 U.S.C. 801 et seq.) to \n        manufacture, distribute, dispense, or possess controlled \n        substances, the Attorney General shall--\n                    (A) grant or deny the application; or\n                    (B) request supplemental information.\n            (2) Additional information.--Not later than 30 days after \n        the Attorney General receives supplemental information as \n        described in paragraph (1)(B) in connection with an application \n        described in paragraph (1), the Attorney General shall grant or \n        deny the application.\n    (e) Information Regarding Denials.--If an application described in \nsubsection (d)(1) is denied, the Attorney General shall provide a \nwritten explanation of the basis of denial to the applicant.\n\nSEC. 6. IMPORTATION OF CANNABIDIOL FOR RESEARCH PURPOSES.\n\n    The Controlled Substances Import and Export Act (21 U.S.C. 951 et \nseq.) is amended--\n            (1) in section 1002(a) (21 U.S.C. 952(a))--\n                    (A) in paragraph (1), by striking ``and'' at the \n                end;\n                    (B) in paragraph (2)(C), by inserting ``and'' after \n                ``uses,''; and\n                    (C) inserting before the undesignated matter \n                following paragraph (2)(C) the following:\n            ``(3) such amounts of marihuana or cannabidiol as are--\n                    ``(A) approved for authorized medical research (as \n                such terms are defined in section 2 of the Cannabidiol \n                Research Expansion Act), or\n                    ``(B) necessary for registered manufacturers to \n                manufacture drugs containing marihuana or cannabidiol \n                that have been approved for use by the Commissioner of \n                Food and Drugs under the Federal Food, Drug, and \n                Cosmetic Act (21 U.S.C. 301 et seq.),''; and\n            (2) in section 1007 (21 U.S.C. 957), by amending subsection \n        (a) to read as follows:\n    ``(a)(1) Except as provided in paragraph (2), no person may--\n            ``(A) import into the customs territory of the United \n        States from any place outside thereof (but within the United \n        States), or import into the United States from any place \n        outside thereof, any controlled substance or list I chemical, \n        or\n            ``(B) export from the United States any controlled \n        substance or list I chemical,\nunless there is in effect with respect to such person a registration \nissued by the Attorney General under section 1008, or unless such \nperson is exempt from registration under subsection (b).\n            ``(2) Paragraph (1) shall not apply to the import or export \n        of marihuana or cannabidiol that has been approved for--\n                    ``(A) authorized medical research authorized under \n                section 5 of the Cannabidiol Research Expansion Act; or\n                    ``(B) use by registered manufacturers to \n                manufacture drugs containing marihuana or cannabidiol \n                that have been approved for use by the Commissioner of \n                Food and Drugs under the Federal Food, Drug, and \n                Cosmetic Act (21 U.S.C. 301 et seq.).''.\n\nSEC. 7. SAFE HARBOR.\n\n    (a) Definitions.--In this section--\n            (1) the term ``adult'' means an individual who is not less \n        than 18 years of age;\n            (2) the term ``child'' means an individual who is not more \n        than 17 years of age;\n            (3) the term ``intractable epilepsy'' means an epileptic \n        seizure disorder for which standard medical treatment--\n                    (A) does not prevent or significantly ameliorate \n                recurring, uncontrollable seizures; or\n                    (B) results in harmful side effects; and\n            (4) the term ``neurologist'' means an allopathic or \n        osteopathic physician board-certified in neurology in good \n        standing and licensed in the State in which the physician \n        practices neurology.\n    (b) Safe Harbor.--Notwithstanding the Controlled Substances Act (21 \nU.S.C. 801 et seq.), the Controlled Substances Import and Export Act \n(21 U.S.C. 951 et seq.), or any other Federal law, it shall not be \nunlawful for--\n            (1) a legal guardian to possess or transport cannabidiol or \n        any other nonpsychoactive component of marihuana for purposes \n        of dispensing the cannabidiol or other nonpsychoactive \n        component to a child of the legal guardian if--\n                    (A) the child has been treated by a neurologist for \n                intractable epilepsy for not less than 6 months;\n                    (B) the child's neurologist attests that other \n                treatment options have not resulted in significant \n                clinical improvement;\n                    (C) the child's neurologist attests that he or she \n                has discussed the currently known potential harms and \n                benefits of using cannabidiol or other nonpsychoactive \n                components of marihuana as a treatment with the child's \n                legal guardian;\n                    (D) the child's neurologist attests that he or she \n                will monitor the child for potential adverse reactions; \n                and\n                    (E) the legal guardian provides documentation for \n                the requirements under subparagraphs (A), (B), (C), and \n                (D);\n            (2) an adult to possess or transport cannabidiol or any \n        other nonpsychoactive component of marihuana if--\n                    (A) the adult has been treated by a neurologist for \n                intractable epilepsy for not less than 6 months;\n                    (B) the adult's neurologist attests that other \n                treatment options have not resulted in significant \n                clinical improvement;\n                    (C) the adult's neurologist attests that he or she \n                has discussed the currently known potential harms and \n                benefits of using cannabidiol or other nonpsychoactive \n                components of marihuana as a treatment with the adult;\n                    (D) the adult's neurologist attests that he or she \n                will monitor the adult for potential adverse reactions; \n                and\n                    (E) the adult provides documentation for the \n                requirements under subparagraphs (A), (B), (C), and \n                (D); or\n            (3) a State-licensed physician to discuss the currently \n        known potential harms and benefits of cannabidiol or any other \n        nonpsychoactive component of marihuana as a treatment with a \n        patient of the physician, or the legal guardian of the patient \n        if the patient is a child.\n    (c) Sunset.--This section shall cease to have force or effect on \nthe date that is 4 years after the date of enactment of this Act.\n\nSEC. 8. FEDERAL RESEARCH.\n\n    The Secretary of Health and Human Services, either directly or \nthrough awarding grants, contracts, or cooperative agreements to \ncovered institutions of higher education, medical or osteopathic \nschools, or practitioners, or a consortia of covered institutions of \nhigher education, medical or osteopathic schools, or practitioners, \nshall expand, intensify, and coordinate the activities of the National \nInstitutes of Health with respect to research on cannabidiol and other \nnonpsychoactive components of marihuana to better determine their \npotential therapeutic effects on serious medical conditions, including \nintractable epilepsy."
}